Exploratory analyses suggested potential biomarkers for BTKi bridging efficacy, including modulation of nicotinamide phosphoribosyltransferase (NAMPT) and programmed cell death protein 1 (PD-1).<h4>Conclusions</h4>Prolonged BTKi bridging might improve the overall response to CAR-T cell therapy in patients with R/R DLBCL, despite the initial disparities. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.